Abatacept

CHEMBL1201823 Phase 4 Disetujui Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A biologic medication that dampens an overactive immune response by blocking a signal that activates T cells, which are the immune cells responsible for causing inflammation and tissue damage in autoimmune diseases. It is used for conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, and is given either as an intravenous infusion or a weekly subcutaneous injection. Patients taking it should avoid live vaccines and be monitored for signs of infection.

Area Terapeutik

Mekanisme Kerja

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A biologic medication that dampens an overactive immune response by blocking a signal that activates T cells, which are the immune cells responsible for causing inflammation and tissue damage in autoimmune diseases. It is used for conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, and is given either as an intravenous infusion or a weekly subcutaneous injection. Patients taking it should avoid live vaccines and be monitored for signs of infection.

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Yes, Abatacept is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201823. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.